Margaret A Fonder, Deborah L Cummins, Benjamin D Ehst, Grant J Anhalt, Jon H Meyerle
{"title":"阿达木单抗治疗顽固性坏疽性脓皮病。","authors":"Margaret A Fonder, Deborah L Cummins, Benjamin D Ehst, Grant J Anhalt, Jon H Meyerle","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To describe a patient with treatment-refractory pyoderma gangrenosum and the outcome of a novel therapeutic approach.</p><p><strong>Methods: </strong>Case report and review of the literature.</p><p><strong>Results: </strong>A patient with inflammatory bowel disease developed severe pyoderma gangrenosum while receiving treatment with the chimeric anti-TNF-alpha antibody infliximab. Despite subsequent trials of numerous immunosuppressive and immunomodulatory medications, the dermatologic disease progressed. The patient's ulcers finally resolved when treatment with adalimumab, a fully humanized monoclonal antibody specific for TNF-alpha, was initiated.</p><p><strong>Conclusions: </strong>We report a novel application of the TNF-alpha inhibitor, adalimumab, in the treatment of pyoderma gangrenosum.</p>","PeriodicalId":87438,"journal":{"name":"Journal of burns and wounds","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2006-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1687150/pdf/","citationCount":"0","resultStr":"{\"title\":\"Adalimumab therapy for recalcitrant pyoderma gangrenosum.\",\"authors\":\"Margaret A Fonder, Deborah L Cummins, Benjamin D Ehst, Grant J Anhalt, Jon H Meyerle\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To describe a patient with treatment-refractory pyoderma gangrenosum and the outcome of a novel therapeutic approach.</p><p><strong>Methods: </strong>Case report and review of the literature.</p><p><strong>Results: </strong>A patient with inflammatory bowel disease developed severe pyoderma gangrenosum while receiving treatment with the chimeric anti-TNF-alpha antibody infliximab. Despite subsequent trials of numerous immunosuppressive and immunomodulatory medications, the dermatologic disease progressed. The patient's ulcers finally resolved when treatment with adalimumab, a fully humanized monoclonal antibody specific for TNF-alpha, was initiated.</p><p><strong>Conclusions: </strong>We report a novel application of the TNF-alpha inhibitor, adalimumab, in the treatment of pyoderma gangrenosum.</p>\",\"PeriodicalId\":87438,\"journal\":{\"name\":\"Journal of burns and wounds\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1687150/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of burns and wounds\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of burns and wounds","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Adalimumab therapy for recalcitrant pyoderma gangrenosum.
Objective: To describe a patient with treatment-refractory pyoderma gangrenosum and the outcome of a novel therapeutic approach.
Methods: Case report and review of the literature.
Results: A patient with inflammatory bowel disease developed severe pyoderma gangrenosum while receiving treatment with the chimeric anti-TNF-alpha antibody infliximab. Despite subsequent trials of numerous immunosuppressive and immunomodulatory medications, the dermatologic disease progressed. The patient's ulcers finally resolved when treatment with adalimumab, a fully humanized monoclonal antibody specific for TNF-alpha, was initiated.
Conclusions: We report a novel application of the TNF-alpha inhibitor, adalimumab, in the treatment of pyoderma gangrenosum.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
